Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Elite Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,459,151

923 payments

Through program year 2025, Elite Clinical Research is reported as receiving $2,459,151 in research payments, across 923 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $620,050 163
2024 Research $340,137 20
2023 Research $156,559 57
2022 Research $247,402 457
2021 Research $164,701 49
2020 Research $418,708 133
2019 Research $511,595 44

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $593,742 51 payments
  2. AstraZeneca Pharmaceuticals LP $568,241 33 payments
  3. Novartis Pharmaceuticals Corporation $433,110 11 payments
  4. GlaxoSmithKline, LLC. $294,635 10 payments
  5. Cipla USA Inc. $174,883 31 payments
  6. Novo Nordisk AS $171,833 502 payments
  7. Boehringer Ingelheim International GmbH $99,249 242 payments
  8. Pfizer Inc. $61,751 23 payments
  9. Boehringer Ingelheim Pharma GmbH & Co.KG $39,496 10 payments
  10. Supernus Pharmaceuticals, Inc. $8,064 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Obesity Long term safety in patients with CV risk $296,667 6 payments
  2. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $287,182 132 payments
  3. A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging $245,171 2 payments
  4. This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio $223,566 11 payments
  5. A Randomized, Double-Blind, Parallel Group, Multicenter, Stratified St $183,760 5 payments
  6. U-Fs-Mu-As3120 $144,468 29 payments
  7. Nn9535-4321 $142,510 172 payments
  8. A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia $128,528 8 payments
  9. A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Eval $110,875 5 payments
  10. A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease $110,711 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record